Smart Pills Statistics 2026: Powerful Trends Ahead

Smart pills are becoming an increasingly important part of digital health, combining ingestible sensors, cameras, wireless communication, and software to support diagnosis, medication monitoring, and targeted treatment. In gastrointestinal care, capsule endoscopy helps clinicians examine areas that may be difficult to reach with conventional endoscopy, while sensor-enabled medications can record ingestion events and provide adherence data to patients and care teams. Emerging systems are also being tested for physiological monitoring, chronic disease management, remote care, and targeted drug delivery.

The market is expanding as health systems look for less invasive diagnostic tools and more reliable ways to monitor treatment outside traditional clinical settings. At the same time, advances in artificial intelligence are making capsule-image analysis faster and more accurate, while miniaturized sensors are enabling new forms of internal monitoring. However, adoption still depends on cost, reimbursement, clinical validation, patient acceptance, privacy protection, and regulatory approval. The following statistics provide a detailed look at the smart pills market, current applications, adoption patterns, clinical research, and future outlook.

Editor’s Choice

• One 2025 industry analysis placed the global smart pills market at $690 million in 2024 when using a narrower definition centered on capsule endoscopy, patient monitoring, and targeted drug delivery.
• Under that narrower scope, worldwide revenue could reach $1.30 billion by 2030.
• That forecast represents an 11.2% CAGR between 2024 and 2030, considerably faster than estimates that use broader market definitions.
• North America generated 53.7% of smart pill revenue in 2023 under the same market methodology.
• The small intestine represented 58.5% of the market by target area in 2023, reflecting the strong role of capsule-based diagnosis in small-bowel disease.
• Capsule endoscopy is projected to grow at a 10.8% CAGR through 2030 in that forecast, supported by its use in gastrointestinal bleeding, tumors, Crohn’s disease, and polyposis syndromes.
• Looking specifically at ingestible sensors, the related global market reached an estimated $1.19 billion in 2025.
• Global ingestible sensor revenue could rise to $2.01 billion by 2030, representing another measure of commercial demand for swallowable sensing technology.

Recent Developments

• An AI-assisted capsule endoscopy system received a U.S. substantial-equivalence decision on March 12, 2026, after its application was submitted on March 5, 2025. The software assists clinicians reviewing small-bowel capsule images for suspected bleeding.
• In a 2025 multicenter clinical validation, AI-assisted capsule reading detected 605 of 635 lesions identified by expert consensus.
• The same trial reported a 96.1% small-bowel lesion detection rate with AI assistance, compared with 76.3% for standard reading.
• AI-assisted sensitivity reached 97.5%, versus 78.2% for conventional capsule review in the multicenter study.
• Mean AI-assisted examination reading time fell to 203 seconds per examination, illustrating how software can address the large image volume generated by capsule endoscopy.
• A separate multicenter study evaluated 259 capsule endoscopy examinations for detecting ulcers and erosions associated with Crohn’s disease.
• In that Crohn’s disease study, AI-assisted reading achieved 90.2% sensitivity, compared with 69.6% for conventional review.
• AI-assisted physicians identified 568 of 600 expert-confirmed lesions, equal to 94.7%, while median reporting time was only 172 seconds per examination.
• Another 2025 research program tested a miniaturized ingestible sensor in 15 healthy volunteers and administered 69 capsules during the clinical evaluation, showing that biochemical and electrochemical smart pill research has moved into initial human testing.
• In June 2026, U.S. regulators formally classified an ingestible gastrointestinal blood-detection capsule as a Class II medical device, creating a defined pathway with special controls for this type of smart capsule.

What Are Smart Pills?

Smart pills are swallowable medical technologies that can contain cameras, sensors, wireless transmitters, electronic components or drug-delivery mechanisms. The term covers several product classes rather than one standardized device. Some capsules image the gastrointestinal tract, some measure biological signals, and others confirm medication ingestion.

• Modern capsule systems are small enough to package sophisticated sensing hardware into a swallowable form. A 2025 biochemical smart capsule measured just 7 millimeters in diameter and 25 millimeters long.
• Another 2025 experimental sensor measured 21 millimeters by 7.5 millimeters, fitting within a standard size-0 capsule form factor.
• That capsule had roughly one-third the volume of typical capsule endoscopes, demonstrating how quickly ingestible electronics are becoming smaller.
• Researchers also reported that the device was approximately three times smaller than a commonly used pH capsule, allowing participants to swallow it more easily.
• The experimental system contained two silver-oxide batteries alongside electrochemical sensors, wireless electronics, and an antenna inside a biocompatible housing.
• Participants gave ease of swallowing an average score of 4.5 out of 5 during the human evaluation.
• Their willingness to swallow multiple capsules again scored even higher at 4.6 out of 5, providing an early indication of usability for repeat monitoring.
• All ingestible devices in the trial passed naturally within eight days, and investigators reported no device-related adverse events.
• The first U.S.-approved drug combined with a digital ingestion-tracking sensor arrived in 2017, marking an early regulatory milestone for medication-linked smart pills.

Smart Pills Market Size and Growth Projections

• The global smart pills market is projected to grow from $2.23 billion in 2025 to $6.64 billion by 2035, nearly tripling over the forecast period.
• In 2026, the smart pills market is expected to reach $2.49 billion, up from $2.23 billion in 2025.
• The market is projected to cross the $3 billion mark in 2028, reaching approximately $3.09 billion.
• By 2030, the global smart pills market is forecast to reach $3.85 billion, about 73% higher than its 2025 value.
• Smart pills market revenue is expected to surpass $4 billion in 2031, climbing to approximately $4.29 billion.
• Growth is projected to accelerate further, with the market rising from $4.78 billion in 2032 to $5.34 billion in 2033.
• By 2034, the smart pills market is forecast to approach the $6 billion milestone, reaching $5.95 billion.
• From 2025 to 2035, the market is projected to add approximately $4.41 billion in value, representing an increase of nearly 198%.

How Smart Pills Work

• One medication-monitoring study followed 21 high-risk cardiovascular patients for 12 weeks using ingestible sensors linked to an external patch and software application.
• Objective sensor data showed that only 57% of those patients achieved at least 80% adherence, despite most patients reporting that they rarely or never missed medication.
• Three patients recorded adherence below 40%, demonstrating how ingestible systems can expose differences between self-reported and directly measured medication use.
• A newer gastrointestinal sensor captured usable measurements from 66 ingestible capsules during its human evaluation, with each capsule transmitting measurements to an external wearable receiver.
• The system simultaneously measured three core variables, redox balance, pH and temperature, as each capsule passed through different sections of the gastrointestinal tract.
• Researchers reported 95th-percentile redox reference values of approximately 230 millivolts in the stomach, -26 millivolts in the small intestine and -323 millivolts in the large intestine, showing how a pill can distinguish biological environments along the digestive tract.
• A newly classified blood-detection capsule uses spectrophotometry, transmitting light through fluid and measuring absorption with optical sensors to determine whether gastrointestinal blood is present.
• In one digital medication system, the approved aripiprazole formulation carries a maximum adult dose of 30 milligrams per day for schizophrenia, while the embedded sensor records ingestion events. However, regulators state that its ability to improve adherence has not been established.
• Clinical experience also shows why smart pills should not automatically be treated as real-time emergency monitors: official labeling states that detection can be delayed or fail to occur, so the ingestion signal should not guide emergency decisions.

Smart Pills Market by Region

• North America accounted for 40.08% of global smart pill revenue in 2025, making it the largest regional market under one current industry estimate.
• North American smart pill revenue reached approximately $950 million in 2025, up from about $890 million in 2024 under the same methodology.
• The U.S. smart pills market is projected to generate about $900 million in 2026, equal to roughly 35.5% of the corresponding global market estimate.
• Europe is projected to reach approximately $690 million in smart pill revenue in 2026, keeping it among the industry’s three largest regional markets.
• Asia-Pacific is projected to reach about $620 million in 2026, while another current market model forecasts an 18.89% regional CAGR from 2025 to 2030.
• Looking specifically at capsule endoscopy, North America generated 43.55% of global revenue in 2025, reinforcing its leadership in one of the most established smart pill applications.
• The U.S. smart pills market was valued at approximately $462 million in 2025 in another market model, compared with $418.3 million in 2024.
• In the smart-pill drug delivery segment, North America held 44.01% of worldwide revenue in 2025, while Asia-Pacific is forecast to grow at 12.98% annually through 2031.
• In smart-pill diagnostics, North America controlled 40.85% of 2025 revenue, while Asia-Pacific is expected to post a 12.31% CAGR through 2031.
• The small-bowel capsule endoscopy segment represented 54.7% of capsule endoscopy revenue in 2025, showing why regions with established gastroenterology infrastructure remain major smart pill markets.

Smart Pills Market by Application

• Targeted smart-pill drug delivery is forecast to grow at a 17.93% CAGR through 2030, making it one of the fastest-growing applications in one recent industry analysis.
• Occult gastrointestinal bleeding accounted for 25.93% of smart pill demand by disease indication in 2024, reflecting the clinical value of capsules in locating otherwise difficult-to-detect bleeding.
• The small intestine represented 42.84% of the market by target area in 2024, consistent with capsule endoscopy’s ability to visualize areas that conventional upper and lower endoscopies may not easily reach.
• Home health care applications are projected to grow at a 15.58% CAGR through 2030, as connected devices increasingly support monitoring outside hospitals.
• Under a broader definition focused specifically on smart-pill drug delivery, global revenue was estimated at $4.83 billion in 2025.
• That drug-delivery market is forecast to reach $8.00 billion by 2030.
• The corresponding drug-delivery forecast represents a 10.61% CAGR between 2025 and 2030.
• In ingestible sensor applications, temperature sensors accounted for about 42% of global revenue in 2024, reflecting their use in physiological monitoring and clinical research.
• Image-based ingestible sensors are projected to expand at a 13.8% CAGR through 2030, supported by continuing improvements in capsule imaging and automated analysis.
• Outside conventional clinical care, sports and fitness applications of ingestible sensors are forecast to grow at a 14.2% CAGR through 2030, showing that swallowable sensor technology is also expanding into performance and heat-stress monitoring.

Smart Pills Adoption Rates in Healthcare

• Hospitals and ambulatory surgery centers are projected to account for 69.1% of smart pill revenue in 2026, showing that institutional health care remains the industry’s primary commercial setting.
• Hospitals generated more than 55.5% of capsule endoscopy revenue in 2025, confirming that most clinical use remains concentrated in hospital-based diagnostic pathways.
• A separate smart-pill diagnostics estimate put hospitals at 48.80% of end-user revenue in 2025, while ambulatory surgery centers are projected to grow at 12.05% annually through 2031.
• Gastrointestinal disorders represented 74.1% of the smart pills market in 2025 under one broad market definition, illustrating how strongly adoption still centers on digestive disease.
• Gastrointestinal bleeding alone generated 39.10% of smart-pill diagnostic demand in 2025, one of the largest individual indications for swallowable imaging devices.
• In a 2025 multicenter study of symptomatic patients, 4,878 people underwent colon capsule endoscopy, providing one of the largest recent real-world datasets on capsule adoption.
• The same 2025 investigation included 10,369 symptomatic patients overall, including 5,025 undergoing conventional colonoscopy and 466 receiving CT colonography for comparison.
• Colon capsule endoscopy was safely tolerated by 98.4% of patients in that large multicenter study.
• A nationwide 2025 Japanese evaluation enrolled 1,006 patients across 44 hospitals, demonstrating adoption across a broad hospital network rather than a single specialized center.
• The Japanese study achieved a total capsule colonoscopy rate of 86.1%, providing a practical measure of how often the swallowed capsule completed the intended examination.

Smart Pills for Medication Adherence

• Reviews of chronic disease care estimate that at least 50% of patients taking long-term medication do not follow their prescribed regimen consistently.
• Medication nonadherence has historically been associated with approximately $100 billion to $290 billion in annual U.S. health care costs, demonstrating the economic rationale behind adherence-monitoring technologies.
• A literature review identified 18 human clinical trials that deployed digital pill systems to assess feasibility and medication-taking behavior.
• Of those 18 investigations, 16 were single-arm pilot studies, showing that much of the early smart-pill adherence evidence came from small feasibility trials rather than large randomized studies.
• Clinical trial durations in that evidence base ranged from one week to six months, covering conditions including HIV, tuberculosis, hepatitis C, schizophrenia, cardiovascular disease and organ transplantation.
• A separate review found that ingestible biosensing systems detected 86.3% of ingestion events across four qualifying studies.
• After accounting for a known transmission issue, the same review estimated that 91.3% of sensor-enabled tablets were successfully detected.
• A systematic review of tuberculosis adherence technologies found ingestible sensors achieved at least 95% sensitivity for dose detection when compared with direct observation.
• In a 12-week cardiovascular study, only 57% of 21 participants reached system-measured adherence of at least 80%, despite most reporting that they rarely or never missed medication.
• Three participants in that cardiovascular study recorded adherence below 40%, illustrating how direct ingestion monitoring can reveal substantial discrepancies between reported and actual medication use.

Smart Pill Usage and Preferences by Age

• Young adults aged 18–24 show the highest smart pill usage or preference level at 55, indicating particularly strong interest among younger consumers.
• The 25–34 age group ranks second with a usage or preference figure of 42, about 13 points lower than the 18–24 group.
• Adults aged 35–44 record a figure of 37, showing that smart pill interest remains relatively high among people in their mid-career years.
• Usage or preference drops considerably to 21 among adults aged 45–54, representing a decline of roughly 43% from the 35–44 group.
• The 55–64 age group records a figure of just 15, highlighting a continued decline in smart pill adoption or preference as age increases.
• People aged 65 and older have the lowest figure at 8, approximately 85% lower than the level recorded among 18–24-year-olds.
• Overall, the data reveals a clear age-related trend, with smart pill usage or preference consistently decreasing across older demographic groups.

Smart Pills in Clinical Trials

• A 2025 multicenter human study tested a miniaturized gastrointestinal sensor in 15 healthy volunteers.
• Researchers administered 69 ingestible capsules across the study’s two phases, with 66 producing data suitable for final analysis.
• The experimental capsule collected gastrointestinal measurements every 20 seconds, producing high-frequency pH, temperature, and oxidation-reduction data as it moved through the body.
• The device measured only 21 millimeters long by 7.5 millimeters wide, approximately one-third the volume of conventional capsule endoscopes.
• A 2025 international remote capsule study enrolled 119 patients across four European centers, including 30 who completed fully remote administration and 89 who used a partially remote pathway.
• Recruitment for that remote capsule study ran from July 2024 through May 2025, providing recent evidence that smart-pill diagnostics can operate partly or entirely outside conventional endoscopy units.
• A randomized trial published in 2026 assigned 159 patients with diverticulitis to colon capsule endoscopy or conventional colonoscopy.
• Of those randomized patients, 148 received their allocated procedure, while 83 completed the subsequent clinical evaluation questionnaires.
• Another colorectal cancer screening trial randomized 368,452 people, making it one of the largest recent studies evaluating where capsule endoscopy could fit within population screening pathways.
• In that trial, fecal screening participation reached 63.4% when capsule endoscopy was offered as a follow-up choice, compared with 64.9% in the standard colonoscopy pathway, indicating that adding capsule choice did not increase initial screening participation.

Smart Pills for Chronic Disease Management

• A cluster-randomized trial of digital medicines included 109 adults with uncontrolled hypertension and type 2 diabetes treated across 12 clinical sites.
• Of the 109 participants, 80 received the digital medicine intervention, and 29 received usual care.
• After four weeks, systolic blood pressure fell by an average of 21.8 mm Hg in digital medicine users compared with 12.7 mm Hg in the usual-care group.
• The adjusted between-group improvement in systolic blood pressure was 9.1 mm Hg, with the advantage remaining evident at 12 weeks.
• Medication adherence remained at 80% or higher while participants used the ingestible-sensor digital medicine system.
• The most frequently reported device-related problem was a self-limited skin rash at the wearable sensor site, affecting 12% of participants, or 10 of 82 people assessed for that event.
• The study population had a mean age of 58.7 years, and 49.5% were women, indicating that the system was evaluated in a clinically diverse middle-aged and older chronic-disease population.
• In 2025 smart-pill diagnostics forecasts, Crohn’s disease represented the fastest-growing diagnostic indication at a projected 12.88% CAGR through 2031.
• A 2025 randomized clinical study specifically evaluated capsule-endoscopy-guided treat-to-target care against continued standard management in patients with quiescent Crohn’s disease, reflecting the shift from one-time diagnosis toward ongoing disease monitoring.
• Current market analysis estimates gastrointestinal disorders represented 74.1% of smart-pill demand in 2025, showing that chronic and recurrent digestive diseases continue to form the largest clinical application base.

Digital Pills Market Share by Mental Health Indication

• Schizophrenia dominates the digital pills market with a 46.8% share, reflecting a strong focus on preventing acute psychotic episodes and supporting medication management.
• Bipolar disorder accounts for approximately 28.0% of the market, making it the second-largest indication, with digital pills used to support treatment adherence and mood stabilization.
• Major depressive disorder (MDD) represents about 18.5% of the market, particularly for adjunctive monitoring in patients with treatment-resistant depression.
• Other mental health conditions hold roughly 6.7% of the market, including applications related to substance use disorders and severe anxiety protocols.
• Combined, schizophrenia and bipolar disorder represent 74.8% of the market, showing that digital pill adoption is heavily concentrated in severe psychiatric conditions.
• The three major indications, schizophrenia, bipolar disorder, and MDD, collectively account for about 93.3% of the market, leaving less than 7% for other psychiatric applications.

Smart Pills for Elderly Care

• A 2024 study specifically examining digital pills in dementia recruited nine people with dementia or cognitive impairment and 15 caregivers to assess feasibility, usability and acceptance.
• Participants living with dementia had a median age of 76, while caregivers had a median age of 75.
• Women represented 56% of participants with dementia, while all 15 caregivers in the study were women.
• Researchers identified five major themes and 15 minor themes related to feasibility, trust, monitoring, cost, and usability, with participants generally receptive to direct ingestion monitoring.
• A 2026 systematic review of digital medication-adherence interventions in adults aged 65 and older included 35 studies, providing a broader picture of the technologies that smart pills will compete with or complement.
• Of those 35 studies, 22 were randomized controlled trials, showing that digital medication support for older adults now has a larger evidence base than ingestible sensors alone.
• Seventeen of the 35 studies, or nearly half, reported improved adherence with digital health interventions compared with baseline or control care.
• Recent U.S. evidence found that more than 4 in 10 adults aged 65 or older used at least five prescription medications during 2017-2020, increasing the complexity that medication-monitoring systems may need to manage.
• Another analysis estimated that 53.0% of U.S. adults aged 65 and older received five or more medications in 2024, compared with 38.8% of adults aged 45-64.
• A 2025 feasibility survey of 30 older adults found that 80% reported difficulty taking medication on time, while 93% owned a smartphone, suggesting both a need for medication support and growing access to devices that can receive smart-pill alerts.

FDA Approvals and Regulatory Status

• Wireless gastrointestinal capsule imaging systems remain Class II medical devices in the U.S. and generally use the 510(k) premarket pathway.
• Colon capsule endoscopy systems are also classified as Class II devices under a separate regulatory category focused on colon visualization and polyp detection.
• Magnetically maneuvered capsule endoscopy systems, which allow an external magnetic controller to steer a swallowed camera through the stomach and duodenum, are regulated as Class II devices.
• Current regulatory records list five substantially equivalent determinations under the magnetically maneuvered capsule category across manufacturer records, showing that controlled capsule navigation has progressed beyond a single authorization.
• In 2026, regulators established a Class II category for ingestible gastrointestinal blood-detection capsules that use optical absorption to detect whether blood is present in the digestive tract.
• AI software designed to analyze prerecorded capsule endoscopy videos now has its own Class II regulatory classification, covering algorithms that flag suspected lesions for clinician review.
• One AI-assisted capsule analysis platform received a substantially equivalent decision on March 12, 2026, after its submission was received on March 5, 2025.
• The current product-life-cycle database lists two cleared or granted AI capsule-analysis systems within this newer software category.
• Ingestible event markers used to confirm medication-taking events are also regulated as Class II devices. The system combines a microsensor, wearable recorder, and software rather than relying on the pill alone.
• The 2025 prescribing information for sensor-enabled aripiprazole describes four connected components: the medicine with an ingestible sensor, a wearable patch, a smartphone application, and a web portal for clinicians or caregivers.

Patient and Healthcare Provider Acceptance of Smart Pills

• A large acceptance study included 2,251 participants, consisting of 767 patients with chronic conditions, 1,238 members of the public, and 246 health care professionals.
• Only 35.3% of patients said they would be willing to take a digital pill.
• Willingness was slightly lower among the general public, at 30.4%.
• Among health care professionals, just 15.8% said they would personally agree to take a digital pill.
• Approximately 72% of health care professionals declined the technology or expressed opposition linked partly to professional and ethical concerns.
• Men were nearly twice as likely as women to report willingness to use digital pills, with an adjusted odds ratio of 1.98.
• People who already checked health information from connected devices every day were 3.42 times more likely to accept digital pills than those without comparable connected-health behavior.
• Sensor safety appeared in 29.5% of responses coded around perceived clinical effectiveness, showing that physical safety remains central to acceptance.
• Concerns that smart pills could function as a form of policing appeared in 15.3% of participants’ coded responses about ethical acceptability.
• Health care professionals also identified cost as a drawback: 16.7% specifically mentioned expense when discussing disadvantages of digital pills.

Cost, Pricing, Insurance Coverage, and Reimbursement

• A sensor-enabled aripiprazole kit has recently carried a cash price of roughly $1,668 for 30 tablets, or about $55.60 per sensor-equipped dose before insurance.
• Another 2025 retail estimate placed the normal out-of-pocket price for a 30-dose kit at about $2,039, while a discount program lowered the quoted amount to roughly $1,664.
• By comparison, published pricing data for some generic 2-mg aripiprazole products showed 30-tablet prices as low as $8.34 to $12.60, illustrating the premium that connected medication technology can add over the underlying drug.
• Medicare Part B recognizes capsule endoscopy under dedicated procedure coding and allows the complete service in several outpatient settings, including physician offices and independent diagnostic environments.
• The technical component of capsule endoscopy can qualify for payment in at least five listed facility or provider-setting categories, including offices, independent diagnostic facilities, federally qualified health centers and rural health clinics.
• Professional interpretation can qualify for payment across six listed setting categories, including inpatient hospitals, outpatient hospitals, offices and public health clinics.
• Current Medicare capsule-endoscopy coverage guidance took effect on March 5, 2026, replacing the version that had been effective since March 6, 2025.
• Medicare also approved a nationwide medical-necessity and documentation review topic for wireless capsule endoscopy on Feb. 24, 2026, showing that reimbursement depends on appropriate clinical indication and documentation rather than device availability alone.
• A 2025 cost-effectiveness model evaluated eight colorectal cancer screening strategies and concluded that colon capsule endoscopy was not cost-effective against biennial fecal testing and 10-year colonoscopy under the modeled assumptions.
• In that model, biennial capsule screening at full adherence increased life-years gained to 155 per 1,000 people, compared with 115 for one fecal-testing strategy, but the additional clinical benefit came at substantially higher cost.

Privacy, Data Security, and Ethical Considerations

• A 2025 review identified privacy concerns in 72% of 83 publications that discussed ethical, legal, and social issues surrounding emerging connected biomedical devices.
• Data sharing appeared as a concern in 53% of the reviewed publications, reflecting uncertainty about access by clinicians, families, manufacturers, insurers and other third parties.
• Hacking and unauthorized access appeared in 51% of the reviewed literature.
• Access to emerging ingestible and implantable technologies appeared in 55% of publications, while affordability or cost appeared in 52%.
• Insurance coverage was raised in 28% of the reviewed publications, connecting privacy and ethics to broader questions of equitable access.
• Concerns about inequity appeared in 41% of the literature analyzed, particularly when expensive connected technologies could become available only to selected patient groups.
• Nearly 47% of publications discussed patient willingness to use the technology, while 30% addressed the importance of shared decision-making.
• Overall, 62% of the analyzed publications took a cautious position toward the ethical issues associated with these emerging electronic health technologies.
• In separate security-design research, 80% of participating experts supported end-to-end encryption for data generated by ingestible biotechnology systems.
• Another 75.6% supported mandatory up-to-date firmware, while 73.3% backed both tighter access controls and formal security standards across connected ingestible-device systems.

Challenges and Future Trends in Smart Pills Technology

• One 2026 market model values the broader global smart pills sector at $4.2 billion in 2026 and projects it to reach $9.8 billion by 2034.
• That forecast implies an 11.2% CAGR through 2034, suggesting continued double-digit expansion under definitions that include diagnostic, monitoring, and drug-delivery capsules.
• In the smart-pill drug-delivery segment, next-generation drug-delivery capsules are forecast to grow at a 14.12% CAGR through 2031.
• Software and analytics platforms connected to smart pills are expected to grow even faster, at a projected 14.45% CAGR through 2031, reflecting greater use of AI and automated interpretation.
• Targeted drug delivery is projected to expand at a 13.18% annual rate, pointing toward pills that do more than passively record data.
• Home health care represents another high-growth channel, with smart-pill applications in that setting forecast to increase at 13.22% annually through 2031.
• Ingestible sensors already accounted for 51.76% of smart-pill drug-delivery component revenue in 2025, underlining their central role in future connected capsule systems.
• Diagnostic imaging held 46.92% of application revenue in 2025, meaning smart pills will likely evolve from a commercially established imaging base rather than from drug delivery alone.
• A capsule-focused market forecast estimates global revenue could rise from $537.8 million in 2025 to $1.3 billion by 2032, driven by continued advances in imaging, monitoring and controlled delivery.
• Within that forecast, smart-pill drug-delivery modes are projected to grow at 14.8% annually and reach about $713.2 million by 2032, indicating that active therapeutic capsules may become a larger part of the market.

Frequently Asked Questions (FAQs)

Conclusion

Smart pills range from established capsule endoscopy systems to AI-assisted diagnostics, medication-ingestion monitors, biochemical sensors and experimental drug-delivery technologies. Their development reflects a broader shift toward connected, minimally invasive and data-driven health care, particularly in gastrointestinal diagnostics, medication adherence, chronic disease management and remote patient monitoring.

Commercial growth remains promising, but the technology is not advancing evenly across every application. Capsule endoscopy already has established clinical use and reimbursement pathways, while digital medication systems and targeted drug-delivery capsules are still developing stronger evidence for routine adoption. Patient willingness, affordability, insurance coverage, data security, and clear clinical value will remain critical factors in determining how widely these systems are used.

Over the coming years, smart pills are likely to become more compact, more connected and increasingly supported by artificial intelligence and automated analytics. If developers can demonstrate reliable clinical outcomes while addressing cost, privacy and usability concerns, smart pills could evolve from specialized diagnostic devices into broader platforms for continuous monitoring, personalized treatment and remote care.